Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

Development of a Calculated Panel Reactive Antibody Web Service with Local Frequencies for Platelet Transfusion Refractoriness Risk Stratification.

Gordon WJ, Ainsworth L, Aronson S, Baronas J, Kaufman RM, Guleria I, Milford EL, Oates M, Paz RD, Yeung MY, Lane WJ.

J Pathol Inform. 2019 Aug 1;10:26. doi: 10.4103/jpi.jpi_29_19. eCollection 2019.

2.

Immunity to X-linked inhibitor of apoptosis protein (XIAP) in malignant melanoma and check-point blockade.

Zhou J, Li J, Guleria I, Chen T, Giobbie-Hurder A, Stevens J, Gupta M, Wu X, Brennick RC, Manos MP, Hodi FS.

Cancer Immunol Immunother. 2019 Aug;68(8):1331-1340. doi: 10.1007/s00262-019-02370-4. Epub 2019 Jul 18.

PMID:
31317218
3.

Preformed Donor-specific Antibodies Against HLA Class II and Graft Outcomes in Deceased-donor Kidney Transplantation.

Uffing A, Hidalgo LG, McMullan C, Perry J, Milford EL, Murakami N, Yeung MY, Guleria I, Wood IG, Akalin E, Azzi J, Chandraker AK, Riella LV.

Transplant Direct. 2019 Apr 15;5(5):e446. doi: 10.1097/TXD.0000000000000893. eCollection 2019 May.

4.

Preface.

Guleria I.

Clin Lab Med. 2019 Mar;39(1):xiii-xiv. doi: 10.1016/j.cll.2018.12.001. No abstract available.

PMID:
30709512
5.

Biomarkers in Fetomaternal Tolerance.

Tripathi S, Guleria I.

Clin Lab Med. 2019 Mar;39(1):145-156. doi: 10.1016/j.cll.2018.11.002. Epub 2018 Dec 17. Review.

PMID:
30709502
6.

Targeting antigen-presenting cells by anti-PD-1 nanoparticles augments antitumor immunity.

Ordikhani F, Uehara M, Kasinath V, Dai L, Eskandari SK, Bahmani B, Yonar M, Azzi JR, Haik Y, Sage PT, Murphy GF, Annabi N, Schatton T, Guleria I, Abdi R.

JCI Insight. 2018 Oct 18;3(20). pii: 122700. doi: 10.1172/jci.insight.122700.

7.

A cloning and expression system to probe T-cell receptor specificity and assess functional avidity to neoantigens.

Hu Z, Anandappa AJ, Sun J, Kim J, Leet DE, Bozym DJ, Chen C, Williams L, Shukla SA, Zhang W, Tabbaa D, Steelman S, Olive O, Livak KJ, Kishi H, Muraguchi A, Guleria I, Stevens J, Lane WJ, Burkhardt UE, Fritsch EF, Neuberg D, Ott PA, Keskin DB, Hacohen N, Wu CJ.

Blood. 2018 Nov 1;132(18):1911-1921. doi: 10.1182/blood-2018-04-843763. Epub 2018 Aug 27.

PMID:
30150207
8.

Repetitive ischemic injuries to the kidneys result in lymph node fibrosis and impaired healing.

Maarouf OH, Uehara M, Kasinath V, Solhjou Z, Banouni N, Bahmani B, Jiang L, Yilmam OA, Guleria I, Lovitch SB, Grogan JL, Fiorina P, Sage PT, Bromberg JS, McGrath MM, Abdi R.

JCI Insight. 2018 Jul 12;3(13). pii: 120546. doi: 10.1172/jci.insight.120546.

9.

Ischemia augments alloimmune injury through IL-6-driven CD4+ alloreactivity.

Uehara M, Solhjou Z, Banouni N, Kasinath V, Xiaqun Y, Dai L, Yilmam O, Yilmaz M, Ichimura T, Fiorina P, Martins PN, Ohori S, Guleria I, Maarouf OH, Tullius SG, McGrath MM, Abdi R.

Sci Rep. 2018 Feb 6;8(1):2461. doi: 10.1038/s41598-018-20858-4.

10.

The impact of screening method on HLA antibody detection before and after lung transplantation: A prospective pilot study.

Cao S, Courtwright AM, Lamattina AM, Guleria I, Burkett P, El-Chemaly S, Goldberg HJ.

J Heart Lung Transplant. 2018 Apr;37(4):531-533. doi: 10.1016/j.healun.2017.11.018. Epub 2017 Nov 22. No abstract available.

11.

Detection and clinical impact of human leukocyte antigen antibodies in lung transplantation: A systematic review and meta-analysis.

Courtwright A, Diamond JM, Wood I, Guleria I, Milford E, El-Chemaly S, Goldberg HJ.

HLA. 2018 Feb;91(2):102-111. doi: 10.1111/tan.13185. Epub 2017 Dec 20.

PMID:
29178607
12.

Divergent Function of Programmed Death-Ligand 1 in Donor Tissue versus Recipient Immune System in a Murine Model of Bronchiolitis Obliterans.

Schütte-Nütgen K, Boenisch O, Harrach H, Casey A, Guleria I, Najafian N, Sayegh MH, Gerard CJ, Subramaniam M.

Am J Pathol. 2017 Jun;187(6):1368-1379. doi: 10.1016/j.ajpath.2017.02.007. Epub 2017 Apr 17.

13.

Novel Application of Localized Nanodelivery of Anti-Interleukin-6 Protects Organ Transplant From Ischemia-Reperfusion Injuries.

Solhjou Z, Uehara M, Bahmani B, Maarouf OH, Ichimura T, Brooks CR, Xu W, Yilmaz M, Elkhal A, Tullius SG, Guleria I, McGrath MM, Abdi R.

Am J Transplant. 2017 Sep;17(9):2326-2337. doi: 10.1111/ajt.14266. Epub 2017 Apr 18.

14.

Testing the Efficacy of Contrast-Enhanced Ultrasound in Detecting Transplant Rejection Using a Murine Model of Heart Transplantation.

Fischer K, Ohori S, Meral FC, Uehara M, Giannini S, Ichimura T, Smith RN, Jolesz FA, Guleria I, Zhang Y, White PJ, McDannold NJ, Hoffmeister K, Givertz MM, Abdi R.

Am J Transplant. 2017 Jul;17(7):1791-1801. doi: 10.1111/ajt.14180. Epub 2017 Feb 1.

15.

The Presence of Pretransplant HLA Antibodies Does Not Impact the Development of Chronic Lung Allograft Dysfunction or CLAD-Related Death.

Zazueta OE, Preston SE, Moniodis A, Fried S, Kim M, Townsend K, Wood I, Boukedes S, Guleria I, Camp P, El-Chemaly S, Rosas IO, Chandraker A, Milford E, Goldberg HJ.

Transplantation. 2017 Sep;101(9):2207-2212. doi: 10.1097/TP.0000000000001494.

PMID:
27893614
16.

Antibodies against HLA-DP recognize broadly expressed epitopes.

Simmons DP, Kafetzi ML, Wood I, Macaskill PC, Milford EL, Guleria I.

Hum Immunol. 2016 Dec;77(12):1128-1139. doi: 10.1016/j.humimm.2016.09.008. Epub 2016 Sep 21.

PMID:
27664843
17.

Association of Donor and Recipient Telomere Length with Clinical Outcomes following Lung Transplantation.

Courtwright AM, Fried S, Villalba JA, Moniodis A, Guleria I, Wood I, Milford E, Mallidi HH, Hunninghake GM, Raby BA, Agarwal S, Camp PC, Rosas IO, Goldberg HJ, El-Chemaly S.

PLoS One. 2016 Sep 2;11(9):e0162409. doi: 10.1371/journal.pone.0162409. eCollection 2016.

18.

Glioproliferative Lesion of the Spinal Cord as a Complication of "Stem-Cell Tourism".

Berkowitz AL, Miller MB, Mir SA, Cagney D, Chavakula V, Guleria I, Aizer A, Ligon KL, Chi JH.

N Engl J Med. 2016 Jul 14;375(2):196-8. doi: 10.1056/NEJMc1600188. Epub 2016 Jun 22. No abstract available.

PMID:
27331440
19.

Multicenter Analysis of Immune Biomarkers and Heart Transplant Outcomes: Results of the Clinical Trials in Organ Transplantation-05 Study.

Starling RC, Stehlik J, Baran DA, Armstrong B, Stone JR, Ikle D, Morrison Y, Bridges ND, Putheti P, Strom TB, Bhasin M, Guleria I, Chandraker A, Sayegh M, Daly KP, Briscoe DM, Heeger PS; CTOT-05 consortium.

Am J Transplant. 2016 Jan;16(1):121-36. doi: 10.1111/ajt.13422. Epub 2015 Aug 10.

20.

Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses.

Liu J, Yuan Y, Chen W, Putra J, Suriawinata AA, Schenk AD, Miller HE, Guleria I, Barth RJ, Huang YH, Wang L.

Proc Natl Acad Sci U S A. 2015 May 26;112(21):6682-7. doi: 10.1073/pnas.1420370112. Epub 2015 May 11.

21.

Effect of TIM-3 Blockade on the Immunophenotype and Cytokine Profile of Murine Uterine NK Cells.

Tripathi S, Chabtini L, Dakle PJ, Smith B, Akiba H, Yagita H, Guleria I.

PLoS One. 2015 Apr 21;10(4):e0123439. doi: 10.1371/journal.pone.0123439. eCollection 2015.

22.

Dendritic Cells in Kidney Transplant Biopsy Samples Are Associated with T Cell Infiltration and Poor Allograft Survival.

Batal I, De Serres SA, Safa K, Bijol V, Ueno T, Onozato ML, Iafrate AJ, Herter JM, Lichtman AH, Mayadas TN, Guleria I, Rennke HG, Najafian N, Chandraker A.

J Am Soc Nephrol. 2015 Dec;26(12):3102-13. doi: 10.1681/ASN.2014080804. Epub 2015 Apr 8.

23.

Role of PD1/PDL1 pathway, and TH17 and treg cells in maternal tolerance to the fetus.

Tripathi S, Guleria I.

Biomed J. 2015 Jan-Feb;38(1):25-31. doi: 10.4103/2319-4170.143511. Review.

24.

Impact of pretransplant anti-HLA antibodies on outcomes in lung transplant candidates.

Kim M, Townsend KR, Wood IG, Boukedes S, Guleria I, Gabardi S, El-Chemaly S, Camp PC, Chandraker AK, Milford EL, Goldberg HJ.

Am J Respir Crit Care Med. 2014 May 15;189(10):1234-9. doi: 10.1164/rccm.201312-2160OC.

PMID:
24749479
25.

Blockade of the programmed death-1 (PD1) pathway undermines potent genetic protection from type 1 diabetes.

Kochupurakkal NM, Kruger AJ, Tripathi S, Zhu B, Adams LT, Rainbow DB, Rossini A, Greiner DL, Sayegh MH, Wicker LS, Guleria I.

PLoS One. 2014 Feb 28;9(2):e89561. doi: 10.1371/journal.pone.0089561. eCollection 2014.

26.

Glomerular inflammation correlates with endothelial injury and with IL-6 and IL-1β secretion in the peripheral blood.

Batal I, De Serres SA, Mfarrej BG, Grafals M, Pinkus GS, Kalra A, Weins A, Bijol V, Rennke HG, Guleria I, Abdi R, Chandraker A, Najafian N.

Transplantation. 2014 May 27;97(10):1034-42. doi: 10.1097/01.TP.0000441096.22471.36.

PMID:
24406453
27.

Comprehensive assessment and standardization of solid phase multiplex-bead arrays for the detection of antibodies to HLA-drilling down on key sources of variation.

Reed EF, Rao P, Zhang Z, Gebel H, Bray RA, Guleria I, Lunz J, Mohanakumar T, Nickerson P, Tambur AR, Zeevi A, Heeger PS, Gjertson D.

Am J Transplant. 2013 Nov;13(11):3050-1. doi: 10.1111/ajt.12462. Epub 2013 Sep 18. No abstract available.

28.

Comprehensive assessment and standardization of solid phase multiplex-bead arrays for the detection of antibodies to HLA.

Reed EF, Rao P, Zhang Z, Gebel H, Bray RA, Guleria I, Lunz J, Mohanakumar T, Nickerson P, Tambur AR, Zeevi A, Heeger PS, Gjertson D.

Am J Transplant. 2013 Jul;13(7):1859-70. doi: 10.1111/ajt.12287. Epub 2013 Jun 13.

29.

B7h (ICOS-L) maintains tolerance at the fetomaternal interface.

Riella LV, Dada S, Chabtini L, Smith B, Huang L, Dakle P, Mfarrej B, D'Addio F, Adams LT, Kochupurakkal N, Vergani A, Fiorina P, Mellor AL, Sharpe AH, Yagita H, Guleria I.

Am J Pathol. 2013 Jun;182(6):2204-13. doi: 10.1016/j.ajpath.2013.02.014. Epub 2013 Apr 8.

30.

TIM-3 regulates innate immune cells to induce fetomaternal tolerance.

Chabtini L, Mfarrej B, Mounayar M, Zhu B, Batal I, Dakle PJ, Smith BD, Boenisch O, Najafian N, Akiba H, Yagita H, Guleria I.

J Immunol. 2013 Jan 1;190(1):88-96. doi: 10.4049/jimmunol.1202176. Epub 2012 Nov 23.

31.

Immune modulation by Lacto-N-fucopentaose III in experimental autoimmune encephalomyelitis.

Zhu B, Trikudanathan S, Zozulya AL, Sandoval-Garcia C, Kennedy JK, Atochina O, Norberg T, Castagner B, Seeberger P, Fabry Z, Harn D, Khoury SJ, Guleria I.

Clin Immunol. 2012 Mar;142(3):351-61. doi: 10.1016/j.clim.2011.12.006. Epub 2011 Dec 30.

32.

The link between the PDL1 costimulatory pathway and Th17 in fetomaternal tolerance.

D'Addio F, Riella LV, Mfarrej BG, Chabtini L, Adams LT, Yeung M, Yagita H, Azuma M, Sayegh MH, Guleria I.

J Immunol. 2011 Nov 1;187(9):4530-41. doi: 10.4049/jimmunol.1002031. Epub 2011 Sep 26.

33.

Anti-CD3 mAb treatment cures PDL1-/-.NOD mice of diabetes but precipitates fatal myocarditis.

Mfarrej B, Keir M, Dada S, Trikudanathan S, Sayegh MH, Sharpe AH, Guleria I.

Clin Immunol. 2011 Jul;140(1):47-53. doi: 10.1016/j.clim.2011.03.011. Epub 2011 Mar 24.

34.

The combination of donor and recipient age is critical in determining host immunoresponsiveness and renal transplant outcome.

Tullius SG, Tran H, Guleria I, Malek SK, Tilney NL, Milford E.

Ann Surg. 2010 Oct;252(4):662-74. doi: 10.1097/SLA.0b013e3181f65c7d.

PMID:
20881773
35.

Differential requirement of CD27 costimulatory signaling for naïve versus alloantigen-primed effector/memory CD8+ T cells.

Yamaura K, Boenisch O, Watanabe T, Ueno T, Vanguri V, Yang J, Tanaka K, Guleria I, Borst J, Zhai Y, Kupiec-Weglinski JW, Najafian N.

Am J Transplant. 2010 May;10(5):1210-20. doi: 10.1111/j.1600-6143.2010.03089.x. Epub 2010 Mar 26.

36.

Multicenter phase I/II trial of the safety of allogeneic endothelial cell implants after the creation of arteriovenous access for hemodialysis use: the V-HEALTH study.

Conte MS, Nugent HM, Gaccione P, Guleria I, Roy-Chaudhury P, Lawson JH.

J Vasc Surg. 2009 Dec;50(6):1359-68.e1. doi: 10.1016/j.jvs.2009.07.108.

37.

Paradoxical functions of B7: CD28 costimulation in a MHC class II-mismatched cardiac transplant model.

Yang J, Riella LV, Boenisch O, Popoola J, Robles S, Watanabe T, Vanguri V, Yuan X, Guleria I, Turka LA, Sayegh MH, Chandraker A.

Am J Transplant. 2009 Dec;9(12):2837-44. doi: 10.1111/j.1600-6143.2009.02839.x. Epub 2009 Oct 21.

38.

Divergent role of donor dendritic cells in rejection versus tolerance of allografts.

Ueno T, Tanaka K, Jurewicz M, Murayama T, Guleria I, Fiorina P, Paez JC, Augello A, Vergani A, Wong M, Smith RN, Abdi R.

J Am Soc Nephrol. 2009 Mar;20(3):535-44. doi: 10.1681/ASN.2008040377. Epub 2009 Jan 7.

39.

Targeting CD22 reprograms B-cells and reverses autoimmune diabetes.

Fiorina P, Vergani A, Dada S, Jurewicz M, Wong M, Law K, Wu E, Tian Z, Abdi R, Guleria I, Rodig S, Dunussi-Joannopoulos K, Bluestone J, Sayegh MH.

Diabetes. 2008 Nov;57(11):3013-24. doi: 10.2337/db08-0420. Epub 2008 Aug 8.

40.

Programmed death 1 ligand signaling regulates the generation of adaptive Foxp3+CD4+ regulatory T cells.

Wang L, Pino-Lagos K, de Vries VC, Guleria I, Sayegh MH, Noelle RJ.

Proc Natl Acad Sci U S A. 2008 Jul 8;105(27):9331-6. doi: 10.1073/pnas.0710441105. Epub 2008 Jul 2.

41.

Critical role of donor tissue expression of programmed death ligand-1 in regulating cardiac allograft rejection and vasculopathy.

Yang J, Popoola J, Khandwala S, Vadivel N, Vanguri V, Yuan X, Dada S, Guleria I, Tian C, Ansari MJ, Shin T, Yagita H, Azuma M, Sayegh MH, Chandraker A.

Circulation. 2008 Feb 5;117(5):660-9. doi: 10.1161/CIRCULATIONAHA.107.741025. Epub 2008 Jan 22.

PMID:
18212277
42.

A link between PDL1 and T regulatory cells in fetomaternal tolerance.

Habicht A, Dada S, Jurewicz M, Fife BT, Yagita H, Azuma M, Sayegh MH, Guleria I.

J Immunol. 2007 Oct 15;179(8):5211-9.

43.

Role of ICOS pathway in autoimmune and alloimmune responses in NOD mice.

Ansari MJ, Fiorina P, Dada S, Guleria I, Ueno T, Yuan X, Trikudanathan S, Smith RN, Freeman G, Sayegh MH.

Clin Immunol. 2008 Feb;126(2):140-7. Epub 2007 Sep 24.

PMID:
17889619
44.

Mechanisms of PDL1-mediated regulation of autoimmune diabetes.

Guleria I, Gubbels Bupp M, Dada S, Fife B, Tang Q, Ansari MJ, Trikudanathan S, Vadivel N, Fiorina P, Yagita H, Azuma M, Atkinson M, Bluestone JA, Sayegh MH.

Clin Immunol. 2007 Oct;125(1):16-25. Epub 2007 Jul 12.

PMID:
17627890
45.

Maternal acceptance of the fetus: true human tolerance.

Guleria I, Sayegh MH.

J Immunol. 2007 Mar 15;178(6):3345-51. Review.

46.

Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway.

Fife BT, Guleria I, Gubbels Bupp M, Eagar TN, Tang Q, Bour-Jordan H, Yagita H, Azuma M, Sayegh MH, Bluestone JA.

J Exp Med. 2006 Nov 27;203(12):2737-47. Epub 2006 Nov 20.

47.

Tissue expression of PD-L1 mediates peripheral T cell tolerance.

Keir ME, Liang SC, Guleria I, Latchman YE, Qipo A, Albacker LA, Koulmanda M, Freeman GJ, Sayegh MH, Sharpe AH.

J Exp Med. 2006 Apr 17;203(4):883-95. Epub 2006 Apr 10.

48.

Differential role of programmed death-ligand 1 [corrected] and programmed death-ligand 2 [corrected] in regulating the susceptibility and chronic progression of experimental autoimmune encephalomyelitis.

Zhu B, Guleria I, Khosroshahi A, Chitnis T, Imitola J, Azuma M, Yagita H, Sayegh MH, Khoury SJ.

J Immunol. 2006 Mar 15;176(6):3480-9. Erratum in: J Immunol. 2006 May 1;176(9):5683.

49.

Infection with Listeria monocytogenes as a probe for placental immunological function.

Barber EM, Guleria I, Pollard JW.

Methods Mol Med. 2006;122:435-42.

PMID:
16512000
50.

A critical role for the programmed death ligand 1 in fetomaternal tolerance.

Guleria I, Khosroshahi A, Ansari MJ, Habicht A, Azuma M, Yagita H, Noelle RJ, Coyle A, Mellor AL, Khoury SJ, Sayegh MH.

J Exp Med. 2005 Jul 18;202(2):231-7.

Supplemental Content

Loading ...
Support Center